the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
Published 1 month ago • 45 plays • Length 2:29Download video MP4
Download video MP3
Similar videos
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
6:38
comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:13
the future of car t-cells and bispecific antibodies to treat myeloma
-
3:44
clinical advances with car-ts and bispecifics in r/r myeloma
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
2:45
emerging treatments for myeloma: quadruplets, bispecific antibodies & car t-cells
-
2:39
the safety and efficacy of hbi0101 for the treatment of r/r myeloma
-
3:22
vaccine safety in the immunocompromised
-
3:56
the future of cancer treatment is here: introducing proton therapy
-
5:35
monitoring the safety of the blood supply
-
3:09
an overview of the toxicities associated with immunotherapy in multiple myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
0:36
promise of gprc5d-targeted car-t therapies in multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
3:59
bispecific t-cell engagers in the treatment of myeloma
-
5:35
safety & efficacy of ari0002h in r/r multiple myeloma
-
5:46
where in the treatment sequence should car t-cells be used for myeloma?